Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma von Sarnaik, Amod A., Hamid, Omid, Khushalani, Nikhil, Lewis, Karl D., Medina, Theresa, Kluger, Harriet M., Thomas, Sajeve S., Domingo-Musibay, Evidio, Pavlick, Anna C., Whitman, Eric D., Martin-Algarra, Salvador, Corrie, Pippa, Curti, Brendan D., Olah, Judit, Lutzky, Jose, Weber, Jeffrey S., Larkin, James M. G., Shi, Wen, Takamura, Toshimi, Jagasia, Madan, Qin, Harry, Wu, Xiao, Chartier, Cecile, Finckenstein, Friedrich Graf, Fardis, Maria, Kirkwood, John M., Chesney, Jason A.

Volltext

OX40 is a potent immune-stimulating target in late-stage cancer patients von Curti, Brendan D, Kovacsovics-Bankowski, Magdalena, Morris, Nicholas, Walker, Edwin, Chisholm, Lana, Floyd, Kevin, Walker, Joshua, Gonzalez, Iliana, Meeuwsen, Tanisha, Fox, Bernard A, Moudgil, Tarsem, Miller, William, Haley, Daniel, Coffey, Todd, Fisher, Brenda, Delanty-Miller, Laurie, Rymarchyk, Nicole, Kelly, Tracy, Crocenzi, Todd, Bernstein, Eric, Sanborn, Rachel, Urba, Walter J, Weinberg, Andrew D

Volltext

Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells von Duhen, Rebekka, Ballesteros-Merino, Carmen, Frye, Alexandra K., Tran, Eric, Rajamanickam, Venkatesh, Chang, Shu-Ching, Koguchi, Yoshinobu, Bifulco, Carlo B., Bernard, Brady, Leidner, Rom S., Curti, Brendan D., Fox, Bernard A., Urba, Walter J., Bell, R. Bryan, Weinberg, Andrew D.

Volltext

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma von Diab, Adi, Tykodi, Scott S., Daniels, Gregory A., Maio, Michele, Curti, Brendan D., Lewis, Karl D., Jang, Sekwon, Kalinka, Ewa, Puzanov, Igor, Spira, Alexander, Cho, Daniel C., Guan, Shanhong, Puente, Erika, Tuan Nguyen, Hoch, Ute, Currie, Sue L., Lin, Wei, Tagliaferri, Mary A., Zalevsky, Jonathan, Sznol, Mario, Hurwitz, Michael E.

Volltext

Recent Advances in the Treatment of Melanoma von Curti, Brendan D, Faries, Mark B

Volltext

Rapid Evolution of Combination Therapy in Melanoma von Curti, Brendan D

Volltext

Science gone translational: the OX40 agonist story von Weinberg, Andrew D., Morris, Nicholas P., Kovacsovics-Bankowski, Magdalena, Urba, Walter J., Curti, Brendan D.

Volltext

Out-of-Sequence Signal 3 Paralyzes Primary CD4+ T-Cell-Dependent Immunity von Sckisel, Gail D., Bouchlaka, Myriam N., Monjazeb, Arta M., Crittenden, Marka, Curti, Brendan D., Wilkins, Danice E.C., Alderson, Kory A., Sungur, Can M., Ames, Erik, Mirsoian, Annie, Reddy, Abhinav, Alexander, Warren, Soulika, Athena, Blazar, Bruce R., Longo, Dan L., Wiltrout, Robert H., Murphy, William J.

Volltext

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition von Buchbinder, Elizabeth I, Dutcher, Janice P, Daniels, Gregory A, Curti, Brendan D, Patel, Sapna P, Holtan, Shernan G, Miletello, Gerald P, Fishman, Mayer N, Gonzalez, Rene, Clark, Joseph I, Richart, John M, Lao, Christopher D, Tykodi, Scott S, Silk, Ann W, McDermott, David F

Volltext

Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma von Feng, Zipei, Puri, Sachin, Moudgil, Tarsem, Wood, William, Hoyt, Clifford C, Wang, Chichung, Urba, Walter J, Curti, Brendan D, Bifulco, Carlo B, Fox, Bernard A

Volltext

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America von Stadler, Walter M., Figlin, Robert A., McDermott, David F., Dutcher, Janice P., Knox, Jennifer J., Miller, Wilson H., Hainsworth, John D., Henderson, Charles A., George, Jeffrey R., Hajdenberg, Julio, Kindwall‐Keller, Tamila L., Ernstoff, Marc S., Drabkin, Harry A., Curti, Brendan D., Chu, Luis, Ryan, Christopher W., Hotte, Sebastien J., Xia, Chenghua, Cupit, Lisa, Bukowski, Ronald M.

Volltext

Systemic immunostimulation induces glucocorticoid-mediated thymic involution succeeded by rebound hyperplasia which is impaired in aged recipients von Collins, Craig P, Khuat, Lam T, Sckisel, Gail D, Vick, Logan V, Minnar, Christine M, Dunai, Cordelia, Le, Catherine T, Curti, Brendan D, Crittenden, Marka, Merleev, Alexander, Sheng, Michael, Chao, Nelson J, Maverakis, Emanual, Rosario, Spencer R, Monjazeb, Arta M, Blazar, Bruce R, Longo, Dan L, Canter, Robert J, Murphy, William J

Volltext

Phase I Study of Recombinant Interleukin-21 in Patients With Metastatic Melanoma and Renal Cell Carcinoma von THOMPSON, John A, CURTI, Brendan D, REDMAN, Bruce G, BHATIA, Shailender, WEBER, Jeffrey S, AGARWALA, Sanjiv S, SIEVERS, Eric L, HUGHES, Steven D, DEVRIES, Todd A, HAUSMAN, Diana F

Volltext

Immunotherapy in Advanced Renal Cancer — Is Cure Possible? von Curti, Brendan D

Volltext

Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study von Curti, Brendan D, Richards, Jon, Hyngstrom, John R, Daniels, Gregory A, Faries, Mark, Feun, Lynn, Margolin, Kim A, Hallmeyer, Sigrun, Grose, Mark, Zhang, Yiwei, Li, Anlong, Andtbacka, Robert H I

Volltext

Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab von Koguchi, Yoshinobu, Iwamoto, Noriko, Shimada, Takashi, Chang, Shu-Ching, Cha, John, Curti, Brendan D, Urba, Walter J, Piening, Brian D, Redmond, William L

Volltext

Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in pat... von Rudin, Charles M, Pandha, Hardev S, Zibelman, Matthew, Akerley, Wallace L, Harrington, Kevin J, Day, Daphne, Hill, Andrew G, O'Day, Steven J, Clay, Timothy D, Wright, Gavin M, Jennens, Ross R, Gerber, David E, Rosenberg, Jonathan E, Ralph, Christy, Campbell, David C, Curti, Brendan D, Merchan, Jaime R, Ren, Yixin, Schmidt, Emmett V, Guttman, Lisa, Gupta, Sumati

Volltext

Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program von Payne, Roxanne, Glenn, Lyn, Hoen, Helena, Richards, Beverley, Smith, 2nd, John W, Lufkin, Robert, Crocenzi, Todd S, Urba, Walter J, Curti, Brendan D

Volltext

Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas von Coveler, Andrew L, Smith, David C, Phillips, Tycel, Curti, Brendan D, Goel, Sanjay, Mehta, Amitkumar N, Kuzel, Timothy M, Markovic, Svetomir N, Rixe, Olivier, Bajor, David L, Gajewski, Thomas F, Gutierrez, Martin, Lee, Hun Ju, Gopal, Ajay K, Caimi, Paolo, Heath, Elisabeth I, Thompson, John A, Ansari, Sahar, Jacquemont, Celine, Topletz-Erickson, Ariel, Zhou, Peigen, Schmitt, Michael W, Grilley-Olson, Juneko E

Volltext

Phase I/II Trial of Temsirolimus Combined With Interferon Alfa for Advanced Renal Cell Carcinoma von MOTZER, Robert J, HUDES, Gary R, DUTCHER, Janice P, CURTI, Brendan D, MCDERMOTT, David F, ESCUDIER, Bernard J, NEGRIER, Sylvie, DUCLOS, Brigitte, MOORE, Laurence, O'TOOLE, Timothy, BONI, Joseph P

Volltext